Trinomab(Zhuhai) key facts
as of Oct 2026- Developer of antibody biopharmaceuticals designed for related medical research services.
- Trinomab(Zhuhai) is valued at approximately $533.7M as of Oct 2026 (last reported valuation).
- It has raised $221.2M; the latest was IPO in Jul 2025.
- Notable investors include GL Ventures, CICC Capital, Shenzhen Guozhong Venture Capital Management, Guolian Investment, Shenzhen Yifeng Investment Management Enterprise — 27 tracked in total.
- Status: In IPO Registration.
Trinomab(Zhuhai)'s last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·The complete investor list: 27 names
- ·Watch Trinomab(Zhuhai): the Monday email on marks, rounds and moves
Trinomab(Zhuhai) funding rounds
No funding rounds for Trinomab(Zhuhai) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Trinomab(Zhuhai)
27+Membership and data by Private Market View
Trinomab(Zhuhai) valuation
Trinomab(Zhuhai)'s last reported valuation was $534 million in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
Trinomab(Zhuhai) investors
27 investors are on record for Trinomab(Zhuhai), including GL Ventures, CICC Capital, Shenzhen Guozhong Venture Capital Management and Guolian Investment. By type, the record holds 4 venture capital firms and 2 private equity firms.
About Trinomab(Zhuhai)
Developer of antibody biopharmaceuticals designed for related medical research services. The company's research revolves around antibodies that can be used to treat viral infections and surgery-caused infections, enabling healthcare providers to prescribe better treatments to their patients.
- Sector
- Healthcare
- HQ
- Zhuhai, China
- Founded
- 2015
- Employees
- 767
- Website
- trinomab.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.